VivoSeq
Infectious Disease

HIV Prevention

2

Pipeline Programs↗

8

Active Trials↗

1

Companies Involved↗

HIV Prevention is an early-stage landscape with 2 programs across 1 company. The most active players are EMPOWERX INC.

Intelligence

Pipeline Metrics

Competitive Density

29/100

Pipeline Velocity

25/100

Mech. Concentration

N/A

Completion Rate

86/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

EMPOWERX INC

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

23

clinical trials

Completed12 · 52%
Recruiting4 · 17%
Not yet recruiting4 · 17%
Withdrawn1 · 4%
Unknown status1 · 4%
Terminated1 · 4%

Clinical Trials

Trial Activity

23 trials

HIV Prevention and Care Interventions for Youth in Uganda
Recruiting·MMU-JHU CARE·Phase 4·NCT06474364·600 enrolled
Optimizing Evidence-based HIV Prevention Targeting People Who Inject Drugs on PrEP
Recruiting·UUniversity of Connecticut·Phase 4·NCT05669534·256 enrolled
Impact of PEP/PrEP Via Pharmacist-Prescribing Implementation (PEPPI)
Recruiting·EEMPOWERX INC·Preclinical·NCT07683117·195 enrolled
Evaluating an Interactive Digital Toolkit for Women's PrEP Implementation
Recruiting·UUniversity of Alabama at Birmingham·Preclinical·NCT07292584·125 enrolled
Sexual Health Access at Retail Pharmacies: Advancing Pharmacy-based Delivery of Primary STI and HIV Prevention for Cisgender Women
Not yet recruiting·UUniversity of Washington·N/A·NCT07361926·720 enrolled
Leveraging Chatbot Technology to Improve PrEP Awareness and Uptake Among Black MSM in the Southern United States
Not yet recruiting·YYale University·Preclinical·NCT05968755·145 enrolled
Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of Polyvalent Env (A, B, C, A/E) / Gag (C) DNA and gp120 (A, B, C, A/E) Protein HIV-1 Vaccines (PDPHV) With Either Alhydrogel or GLA-SE in Healthy Adults Living Without HIV
Not yet recruiting·WWorcester HIV Vaccine·Phase 2·NCT07675629·126 enrolled
Migration, Social Bonds, Transnationalism, and HIV Prevention Pathways Among African Immigrants (MiST-Pathways)
Not yet recruiting·SState University of New York at Buffalo·Preclinical·NCT07565584·144 enrolled
Comprehensive HIV Prevention Package for MSM in Southern Africa: Pilot Study (Sibanye Health Project)
Completed·EEmory University·N/A·NCT02043015·100 enrolled
PK and PD Study of Oral F/TAF for HIV Prevention
Completed·CCONRAD·Phase 1·NCT02904369·73 enrolled
Gender-Specific Combination HIV Prevention for Youth in High Burden Settings (MP3-Youth)
Completed·NNew York University·N/A·NCT01571128·1,215 enrolled
Optimization of a Tenofovir Enema for HIV Prevention
Completed·JJohns Hopkins University·Phase 1·NCT02750540·21 enrolled
SEARCH CAB LA Dynamic Choice HIV Prevention Study Extension
Completed·UUniversity of California, San Francisco·Phase 4·NCT05549726·984 enrolled
Comprehensive HIV Prevention Package for MSM in Port Elizabeth
Completed·EEmory University·N/A·NCT02449733·101 enrolled
Early Antiretroviral Therapy and Pre-exposure Prophylaxis for HIV Prevention Among Female Sex Workers in Cotonou, Benin
Completed·—·Phase 4·NCT02237027·361 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)